Today, in the face of illness, millions of people are confronted with medical uncertainty. As patients and their physicians seek an accurate diagnosis of their condition, precision diagnostics are playing important new roles in medicine, and are helping to inspire the growing presence of targeted treatments that define precision medicine today.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care.
The Company focuses on the development of innovative immunodiagnostic agents and immunotherapeutics that can and will make a difference for individuals, as well as their families, physicians and care givers, touched by devastating conditions like cancer, autoimmune, infectious and inflammatory diseases. For patients and physicians, we aspire to provide innovative immunodiagnostic agents and therapies to improve patient care for serious diseases. For investors, we aim to deliver superior growth through our focus developing our innovative Manocept™ platform and driving efficient business processes. For our employees, we provide a culture that focuses on the direct contributions our efforts make for the patients we serve and an innovative development environment for new breakthrough products.
On March 3, 2017, Navidea completed the sale of the North American rights to Lymphoseek® to Cardinal Health 414, receiving approximately $98 million, with the opportunity to earn up to $227 million of additional consideration through 2026.
Navidea’s Management Team and Board of Directors are leaders in research, development, and commercialization of precision diagnostic and radiopharmaceutical imaging agents.